Fighting Myalgic Encephalomyelitis/Chronic Fatigue
Despite Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) affecting millions worldwide, few have the knowledge to appropriately diagnose or manage this debilitating condition. Unfortunately, clinical guidance has been scarce, and in some cases suffers spend years searching for a diagnosis. We know that more than 90% of Australian sufferers remain undiagnosed, and those diagnosed often receive inappropriate treatment. This is of significant importance, because after acute COVID-19, a significant percentage of sufferers remain ill for many months with an illness similar to ME/CFS.
There are many steps we can take to improve the health, function, and quality of life of
those with ME/CFS, including those who develop ME/CFS after COVID-19 infection. Patients with lingering illness following acute COVID-19 who do not fully meet criteria for ME/CFS may also benefit from these approaches.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, multi-system disease affecting millions worldwide. Post Covid-19 infection, we are seeing an increase in presentations of patients with ME/CFS.
Despite its high prevalence and disabling nature, medical education programs rarely
cover ME/CFS and guidance for practicing clinicians is often outdated and inappropriate.
With over 20 years’ experience treating ME/CFS, Elixir’s specialists are going to unpack this condition, its cause and the latest in treatment protocols.
Over the next few weeks, the team at Elixir Compounding Pharmacy will publish a special blog on fighting ME/CFS. If you or a loved one is struggling with chronic fatigue, be sure to tune in!